logo

Theravance Biopharma Inc. (TBPH)



Trade TBPH now with
  Date
  Headline
7/2/2020 6:02:21 AM Theravance Biopharma Appoints Deepika Pakianathan To Its Board
6/25/2020 6:03:48 AM Theravance Biopharma Says COVID-19 Patient Dosed In Phase 2 Study Of TD-0903
4/23/2020 6:04:18 AM Theravance: First Subject Dosed In Phase 1 Study Of TD-0903 For Acute Lung Injury Due To COVID-19
4/20/2020 6:05:02 AM Theravance Biopharma Announces Peer-Reviewed Publication Highlighting TD-1473 Program In Journal Of Crohn's And Colitis
4/9/2020 7:04:08 AM Theravance Biopharma Responds To COVID-19 Pandemic By Advancing TD-0903 To Treat Patients With Acute Lung Injury
3/2/2020 7:13:21 AM Theravance Biopharma Announces Closing Of Private Placement Of $400 Mln Non-Recourse Notes
2/11/2020 11:08:02 PM Theravance Biopharma Prices Public Offering Of 5.5 Mln Ordinary Shares At $27/Shr
2/10/2020 4:04:23 PM Theravance Biopharma Announces Proposed Public Offering Of Ordinary Shares
12/23/2019 8:17:58 AM Theravance Biopharma, Pfizer Enter Global License Deal For Skin-Targeted, Locally-Acting Pan-JAK Inhibitor Program
12/3/2019 7:54:21 AM Theravance Biopharma Announces Dosing Of First Patient In Phase 2 Allergen Challenge Study Of TD-8236
9/9/2019 7:06:59 AM Theravance Biopharma Reports Positive Results From Phase 1 Clinical Trial Of TD-8236
7/31/2019 7:25:17 AM Theravance Biopharma Q2 Net Loss $39.8 Mln Vs. Net Loss $40.8 Mln Last Year
7/22/2019 8:20:49 AM Theravance Biopharma Reports New Data From Phase 2 Study Of Ampreloxetine At 32nd European Neurology Congress
6/18/2019 9:19:19 AM Theravance Reports Data From Phase 2 Study Of Ampreloxetine; Data Supports Phase 3 Program In Symptomatic NOH
6/14/2019 8:12:44 AM Theravance Biopharma, Mylan Expand YUPELRI Development, Commercialization Agreement
6/4/2019 8:31:26 AM Theravance Biopharma Appoints Andrew Hindman As SVP And CFO
5/21/2019 7:05:51 AM Theravance Biopharma Reports Data From Phase 1b Study Of TD-1473 In Oral Presentation At DDW 2019